Plus Therapeutics announces FDA conditionally accepted name REYOBIQ
Plus Therapeutics (PSTV) announces the U.S. Food and Drug Administration, FDA, has conditionally accepted the Company’s new proprietary name, ...
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma ...
The Lewiston Tribune10h
Prosecutor: Kohberger bought Ka-Bar knife before murders
Among the numerous court documents released Wednesday in the Bryan Kohberger case, the prosecution included details about his ...
Plus Therapeutics Inc.: Plus Therapeutics Introduces REYOBIQ, FDA-Accepted Proprietary Name for Lead Drug Candidate
REYOBIQ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus ...
Fierce, Compassionate and Genuine: Buckley Bala Wilson Mew Announces Passing of Founding Partner Edward D. Buckley
"Ed was not only a ferocious fighter for the civil rights of disadvantaged workers but he was a generous soul—a compelling ...
essanews.com on MSN12h
Russian company acquires Ericsson trademark amidst changes
The Russian company Ruskliemat registered the trademark Ericsson after the Swedish manufacturer left Russia. This marks the ...
Daily Wrap on MSN17h
Ericsson trademark in Russia: New chapter for foreign brands
The Russian company "Ruskliemat registered the Ericsson trademark after the Swedish manufacturer exited Russia. This marks ...